Biohaven signs exclusive Asian licensing deal with Ono Pharma for IgG degrader portfolio
Biohaven Ltd. entered an exclusive licensing agreement with Japan's Ono Pharmaceutical to develop and commercialize its MoDE IgG degrader portfolio, including lead candidate BHV-1300, in Japan, South Korea, Taiwan and ASEAN countries. Under the deal, Ono will pay $80 million upfront and a $20 million milestone payment expected within a year, plus roughly 20 % royalties on net sales. Biohaven retains all rights to the portfolio outside the licensed territories.
Why it matters
The upfront cash provides non‑dilutive capital for Biohaven, while the royalty stream could add ongoing revenue if the products launch in Asia. The agreement also expands the geographic reach of BHV-1300, potentially accelerating its market entry in high‑growth Asian markets.
Key facts
- 1Biohaven will receive $80 million upfront at execution of the agreement. prnewswire.com
- 2A $20 million milestone payment is payable upon achievement anticipated within a year. prnewswire.com
- 3Ono will pay approximately 20 % royalties on net sales in the licensed territory. prnewswire.com
- 4The exclusive license covers Japan, South Korea, Taiwan and ASEAN countries. prnewswire.com
- 5Biohaven retains rights to the MoDE IgG degrader portfolio outside the licensed territory, including the United States, Europe and China. prnewswire.com
- 6Lead candidate BHV-1300 is in a pivotal Phase 3 trial for Graves' disease. marketscreener.com
Summary written by AlphAI from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.